Two notable questions relating to Keller and colleagues' findings are when continentalcrust formation started, and whether crustal formation processes have varied over Earth's history -topics that two of the authors of this work wrestled with in an earlier paper 10
. Statistical evidence in the present data set suggests that the composition of the population of rocks more than 100 million years old does not vary substantially from that of the younger population. But the data set for older rocks is much smaller than that for younger ones, and many of the older rocks have been lost through recycling processes such as sub duction and erosion; those that survived recycling may not be representative of the diversity that once existed. The observations now presented by Keller et al. are therefore most applicable to modern continental-crust formation.
In an era in which breakthroughs in geochemistry are often attained by probing rocks and minerals at the nanometre and atomic scales 11 , Keller et al. are pushing the boundaries in the other direction, reminding us of the value of investigations averaged over large scales of time and space. Since the pioneering days of Bowen and Daly, the field of geochemistry has evolved to incorporate observations ranging from the microscopic to the global in scale. Future work will require the integration of such geochemical observations with those from a wide range of other disciplines to explore questions such as whether the formation of the continental crust played a primary part in the rise of oxygen in Earth's atmosphere. ■ evidence -including data from geological samples, seismic imaging, elemental massbalance calculations and numerical simulations -support a model in which mafic crystal residues can reach a density greater than that of the uppermost mantle, causing them to detach from the base of the continental crust and sink back into the mantle, a process called delamination [4] [5] [6] [7] [8] . Keller et al. identify key differences between the average plutonic and volcanic rock compositions from convergent and rift environments. These differences are consistent with predicted cumulate compositions, based on the authors' extensive calculations, and demonstrate that maficcrystal cumulates are present in plutonic rocks, but not in large abundances. The authors' observation that most continental plutonic-rock compositions have higher silica content than expected for mafic cumulates substantiates both Bowen's hypothesis and the delamination model.
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Keller et al. also conclude that plutonic rocks that formed in continental-rift environments exhibit characteristics consistent with the presence of water during their formation. Such environments were previously thought to be dry. The presence of water could explain why these magmas stalled and crystallized in the continental crust instead of erupting at the surface: water-containing magmas approach the temperature at which crystals start to form as they ascend, whereas dry magmas do not. Ultimately, the bulk continental crust has geochemical signatures consistent with formation in the presence of small amounts of water 9 . The observation that both convergent and rift plutonic environments produce such signatures, and that they preferentially crystallize in the crust rather than erupt, therefore provides new constraints on theories of how the continental crust developed. Mafic minerals (those with the highest abundance of iron and magnesium) are the first to crystallize and fall to the bottom of the melt, where they form rocks known as mafic cumulates. The remaining melt is enriched in silica and forms the continental crust. b, In the assimilation model, ascending mantle-derived magmas drive the melting of the pre-existing continental crust, which mixes into the magma. The resulting mixture goes on to form new continental crust. Keller and colleagues' compilation 1 of geochemical data from around the globe supports the idea that crystallization is the dominant process in modern continental-crust formation.
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A dendritic-cell brake on antitumour immunity
Activation of a cellular stress response and the transcription factor XBP1 in dendritic cells has now been shown to limit the cells' ability to stimulate antitumour immune responses in a mouse model of ovarian cancer.
ells in the microenvironment of a tumour are exposed to stressful events. This is due in part to a lack of oxygen and nutrients that leads to malfunction of the endoplasmic reticulum (ER), the cellular organelle responsible for protein folding. The result is an accumulation of unfolded proteins -a state referred to as ER stress. Cancer cells use a signalling pathway known as the ER stress response to survive in this environment. Whether this pathway also affects non-cancer cells in the tumour microenvironment, which are exposed to similar conditions, was not known. Writing in Cell, Cubillos-Ruiz et al. 1 show, in a model of ovarian cancer, that induction of the ER stress response in tumour-associated dendritic cells disrupts the cells' ability to promote adaptive antitumour immunity.
Dendritic The key role of T-cell responses in cancer treatment has been firmly established in recent years through the remarkable clinical success of strategies aimed at increasing the activation of tumour-targeting T cells. These therapies operate through the engineering of T cells to carry receptors that bind strongly to tumour antigens or by blocking inhibitory molecules on T cells to increase T-cell function. However, only subsets of patients respond to these treatments, and there is an urgent need to identify other brakes on antitumour immunity.
Although interactions between T cells and DCs typically occur in tissue-draining lymph nodes, it is now clear that DC presentation of tumour antigens also occurs in the tumour itself, suggesting that DCs in the tumour microenvironment can substantially influence the functions of antitumour T cells. Thus, it is crucial to assess the characteristics of tumourassociated DCs and to identify molecules for maximizing local antigen presentation that might also be potential drug targets. Altered DC function is common in tumours, and different mechanisms that underlie DC dysregulation in the tumour microenvironment have been identified, including reduced DC accumulation at the tumour site 3 and increased immuno suppression induced by soluble factors (cytokines) that are produced by tumour cells or their surrounding tissue 4 . The ER stress response is mediated by several signalling molecules, among which the enzyme IRE1α and its target transcription factor XBP1 are the most evolutionarily conserved. XBP1 has been shown to promote tumour growth when expressed in cancer cells 5 . Using a mouse model of ovarian cancer, Cubillos-Ruiz et al. show that damaging molecules called reactive oxygen species (ROS) accumulate in tumour-associated DCs, and that ROS cause lipid degradation (by peroxidation) and the accumulation of lipid by-products, which in turn leads to the ER stress response and XBP1 activation (Fig. 1) . Analysis of the genes expressed by these DCs revealed that a lipid-synthesis program is induced in XBP1-expressing cells but not in those lacking XBP1.
The authors went on to show that deletion of the gene that encodes XBP1 in cells expressing CD11c (an integrin protein expressed at high levels on DCs), or delivery of short inhibitory RNA molecules that inhibit XBP1 expression, led to reduced lipid accumulation in DCs, increased DC antigen-presentation capacity, greater accumulation of T cells in the ovarian tumours and reduced tumour growth. Scavenger molecules that eliminate lipids and reduce ROS levels similarly improved DC antigenpresentation ability, suggesting that XBP1's function in enhancing tumour formation is at least partly due to the induction of lipid biosynthesis in DCs.
Although DCs express high levels of CD11c in the steady state, other APCs such as macrophages and monocyte-derived cells can also express CD11c (ref. 2) , and so the therapeutic benefit of XBP1 deletion in CD11c-expressing (CD11c + ) cells might not solely reflect its effect on DCs. XBP1 has an important role in the physiology of APCs under homeostatic conditions: deletion of XBP1 in non-tumour DCs compromises their survival 6 and antigen-presentation ability 7 , and loss of XBP1 in activated macrophages reduces cytokine release in response to microbial stimuli 8 . These findings contrast with Cubillos-Ruiz and colleagues' demonstration that XBP1 deletion in tumour-associated CD11c + cells does not compromise DC survival and improves their antigen-presentation function. Such surprising results suggest that the pro-immunogenic homeostatic function of XBP1 is subverted in tumour-associated DCs. The extent to which the tumour or its environment promotes XBP1 activation or subverts its function should be explored further.
Increased lipid accumulation has been observed in tumour-associated CD11c + cells in tumour-bearing mice and in patients with cancer 9 . Whether the lipid-laden CD11c + cells described in these studies represent bona fide DCs, monocyte-derived cells or macrophages will need to be addressed by cell-specific assays. Lipid accumulation in macrophages has also been linked to neurodegenerative diseases and atherosclerosis, and it will be interesting to explore whether XBP1 contri butes to the progression of these conditions.
Cubillos-Ruiz and colleagues' results extend previous studies 10, 11 showing that metabolic changes, for example increased breakdown of the amino acids arginine and tryptophan in tumour-associated DCs, alter T-cell effector function. Greater understanding of the extent of metabolic alterations in tumour-associated DCs should help to identify yet other pathways of immune dysregulation in tumours. In the meantime, the authors' finding that XBP1 deletion in DCs increases T-cell infiltration of tumours and reduces tumour growth is a timely addition to the pressing search for targets that increase antitumour T-cell function. ■ 1 show that damaging molecules called reactive oxygen species (ROS), which are produced in tumour-associated DCs, induce an endoplasmic reticulum (ER) stress response. The ER stress pathway leads to expression of the transcription factor XBP1, which induces lipid synthesis. The resulting accumulation of lipids in the DCs reduces their ability to present antigens and thus impairs antitumour T-cell responses. Macrophage cells may also contribute to the ER stress response.
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